Create Free Account

By creating account you will get access to hot stocks & personalised emails

Pro Medicus Ltd

Healthcare AU PME

204.72AUD
0.09(0.04%)

Last update at 2024-11-13T05:10:00Z

Day Range

200.90205.24
LowHigh

52 Week Range

83.93200.50
LowHigh

Fundamentals

  • Previous Close 204.63
  • Market Cap20899.80M
  • Volume109052
  • P/E Ratio253.16
  • Dividend Yield0.22%
  • EBITDA113.06M
  • Revenue TTM161.50M
  • Revenue Per Share TTM1.55
  • Gross Profit TTM 126.79M
  • Diluted EPS TTM0.79

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 86.13M 63.08M 42.87M 30.02M 26.12M
Minority interest - - - - -
Net income 60.65M 44.44M 30.85M 23.08M 23.08M
Selling general administrative 24.07M 15.40M 13.53M 12.85M 12.13M
Selling and marketing expenses 2.52M 1.95M 0.32M 1.49M 1.57M
Gross profit 124.24M 92.94M 67.35M 56.42M 48.67M
Reconciled depreciation 7.93M 7.32M 7.20M 7.68M 6.08M
Ebit 83.76M 62.33M 42.33M 30.02M 25.44M
Ebitda 91.69M 69.64M 49.53M 37.71M 31.52M
Depreciation and amortization 7.93M 7.32M 7.20M 7.68M 6.08M
Non operating income net other - - - - -
Operating income 84.08M 61.31M 42.63M 30.07M 25.44M
Other operating expenses 40.12M 30.10M 24.21M 26.26M 24.64M
Interest expense 0.39M 0.65M 0.54M 0.00500M 0.68M
Tax provision 25.48M 18.64M 12.02M 6.94M 7.00M
Interest income 2.43M 0.65M 0.18M 0.17M 0.24M
Net interest income 2.43M 0.65M 0.18M 0.17M 0.24M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 25.48M 18.64M 12.02M 6.94M 7.00M
Total revenue 124.79M 93.40M 67.84M 56.78M 50.08M
Total operating expenses 40.48M 30.61M 25.01M 26.40M 23.23M
Cost of revenue 0.54M 0.47M 0.49M 0.35M 1.41M
Total other income expense net -0.06600M 0.10M 0.36M -0.17700M 0.68M
Discontinued operations - - - - -
Net income from continuing ops 60.65M 44.44M 30.85M 23.08M 19.12M
Net income applicable to common shares 60.65M 44.44M 30.85M 23.08M 19.12M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 257.43M 202.13M 157.05M 125.57M 95.64M
Intangible assets 20.07M 21.35M 22.29M 20.01M 18.84M
Earning assets - - - - -
Other current assets 1.89M 0.78M 0.45M 1.57M 1.03M
Total liab 69.70M 63.36M 55.32M 43.89M 35.46M
Total stockholder equity 187.73M 138.78M 101.73M 81.68M 60.18M
Deferred long term liab - 2.36M 1.47M 1.35M 0.76M
Other current liab 15.21M 16.56M 14.48M 7.29M 4.13M
Common stock 23.65M 1.96M 1.96M 1.96M 1.96M
Capital stock 23.65M 1.96M 1.96M 1.96M 1.96M
Retained earnings 173.36M 127.12M 92.58M 66.92M 49.62M
Other liab - 31.31M 26.78M 24.23M 20.99M
Good will - - - - -
Other assets 0.00000M 12.45M 47.19M 43.03M 40.53M
Cash 60.06M 91.25M 63.66M 42.04M 43.41M
Cash and equivalents - - - - -
Total current liabilities 34.56M 30.85M 26.86M 17.62M 12.72M
Current deferred revenue 17.05M 12.60M 10.13M 8.89M 7.22M
Net debt -57.99300M -89.39700M -61.37700M -39.42100M -41.13700M
Short term debt 0.55M 0.65M 0.60M 0.57M 0.52M
Short long term debt - - - - -
Short long term debt total 2.07M 1.85M 2.28M 2.62M 2.28M
Other stockholder equity - -129.07500M -94.53500M -68.88400M -51.58200M
Property plant equipment - 2.19M 2.60M 3.01M 2.85M
Total current assets 206.56M 163.79M 119.82M 87.57M 61.48M
Long term investments 7.34M - - - -
Net tangible assets - 117.43M 79.44M 61.67M 41.34M
Short term investments 95.36M 30.25M 26.90M 19.78M 19.78M
Net receivables 49.20M 39.88M 27.44M 22.84M 13.84M
Long term debt - - - - -
Inventory 0.05M 0.06M 0.08M 0.03M 0.04M
Accounts payable 1.74M 1.03M 1.64M 0.87M 0.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -9.27700M 9.70M 7.20M 12.80M 8.60M
Additional paid in capital - - - - -
Common stock total equity - - - - 1.96M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.04M 2.60M 1.47M 1.39M 0.99M
Deferred long term asset charges - - - - -
Non current assets total 50.86M 38.34M 37.23M 38.01M 34.16M
Capital lease obligations 2.07M 1.85M 2.28M 2.62M 2.28M
Long term debt total - 1.20M 1.68M 2.04M 1.75M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -7.55700M -8.53300M -19.70400M -7.69900M -7.30500M
Change to liabilities 7.14M 8.10M 4.16M -1.32400M 7.29M
Total cashflows from investing activities -7.55700M -16.90700M -27.21700M -7.69900M -7.30500M
Net borrowings -0.57400M -0.50900M -0.50100M -0.55700M -0.55700M
Total cash from financing activities -27.52700M -23.31400M -14.04900M -12.31500M -9.84300M
Change to operating activities 0.27M 0.35M 0.26M -0.12900M 0.10M
Net income 60.65M 44.44M 30.85M 23.08M 19.12M
Change in cash 27.59M 21.62M -1.37400M 11.10M 7.08M
Begin period cash flow 63.66M 42.04M 43.41M 32.31M 25.24M
End period cash flow 91.25M 63.66M 42.04M 43.41M 32.31M
Total cash from operating activities 62.53M 61.58M 38.84M 31.42M 24.66M
Issuance of capital stock - - - - -
Depreciation 0.83M 0.81M 0.80M 0.84M 6.08M
Other cashflows from investing activities -1.11100M 0.65M 0.18M 0.17M 0.24M
Dividends paid 26.11M 18.79M 13.55M 10.92M 9.84M
Change to inventory 0.02M -0.04300M 0.00100M -0.00400M 0.02M
Change to account receivables -13.47800M -3.59100M -9.53900M 4.80M -9.08900M
Sale purchase of stock -0.84500M -4.01700M -4.01700M -0.84200M -0.84200M
Other cashflows from financing activities -0.57400M -0.50900M -0.50100M -0.55700M 0.84M
Change to netincome -0.24000M 0.40M 2.07M 3.63M 1.19M
Capital expenditures 6.45M 9.02M 7.69M 7.87M 7.55M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -13.45600M -3.63400M -9.53800M 4.79M -8.96100M
Stock based compensation 1.23M 0.03M 0.68M 0.65M 0.78M
Other non cash items 1.05M 16.32M 7.19M 7.50M 5.34M
Free cash flow 56.09M 52.55M 31.15M 23.55M 17.11M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PME
Pro Medicus Ltd		 0.09 0.04% 204.72 253.16 133.33 129.41 110.25 127.26 170.22
ONE
Oneview Healthcare PLC		 -0.005 1.56% 0.32 - - 23.67 26.45 13.67 -3.5247
CGS
CogState Ltd		 -0.005 0.51% 0.97 19.40 22.37 3.86 2.71 1.88 8.24
MDR
Medadvisor Ltd		 -0.005 1.96% 0.25 - 25.97 1.20 2.67 1.10 19.13
M7T
Mach7 Technologies Ltd		 -0.005 1.27% 0.39 - - 2.98 1.72 3.73 41.71

Reports Covered

Stock Research & News

View All

Profile

Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company was incorporated in 1983 and is headquartered in Richmond, Australia.

Pro Medicus Ltd

450 Swan Street, Richmond, VIC, Australia, 3121

Key Executives

Name Title Year Born
Dr. Sam Aaron Hupert M.B.B.S., M.D. Co-Founder, CEO, MD & Exec. Director NA
Mr. Anthony Barry Hall B.Sc., B.Sc.(Hons), M.Sc. Co-Founder, Technology Director & Exec. Director NA
Mr. Clayton James Hatch CPA, B.Comm, CPA CFO & Company Sec. NA
Dr. Malte Westerhoff GM of Europe & Global CTO NA
Mr. Brad Levin GM of North America & Global Head of Marketing NA
Mr. Sean Lambright Global Head of Sales - Visage Imaging Inc NA
Ms. Teresa Gschwind Global Head of Customer Service of Visage Imaging Inc. NA
Dr. Sam Aaron Hupert M.B.B.S., M.D. Co-Founder, CEO, MD & Executive Director NA
Mr. Anthony Barry Hall B.Sc., B.Sc.(Hons), M.Sc. Co-Founder, Technology Director & Executive Director NA
Mr. Clayton James Hatch B.Comm, CPA, CPA Chief Financial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.